Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:DRUG NASDAQ:FDMT NASDAQ:GNFT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.410.0%$0.39$0.30▼$10.62$58.63M1.823.46 million shs1.18 million shsDRUGBright Minds Biosciences$24.81-4.3%$28.49$0.94▼$79.02$182.65M-6.01826,284 shs19,887 shsFDMT4D Molecular Therapeutics$4.28-1.6%$3.86$2.24▼$28.93$201.51M2.81810,031 shs183,304 shsGNFTGENFIT$3.65-2.7%$4.10$2.55▼$6.42$187.51M1.0810,427 shs5,487 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-0.05%+22.82%+11.32%+11.38%-92.10%DRUGBright Minds Biosciences-4.32%-12.33%-10.59%-13.94%+2,381.00%FDMT4D Molecular Therapeutics-1.61%+4.52%-1.83%+62.74%-81.56%GNFTGENFIT-2.67%-4.45%-14.12%+7.67%-16.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.3439 of 5 stars3.33.00.04.72.21.71.3DRUGBright Minds Biosciences2.2807 of 5 stars3.62.00.00.02.32.50.0FDMT4D Molecular Therapeutics2.1813 of 5 stars3.33.00.00.01.31.70.6GNFTGENFIT2.3147 of 5 stars3.55.00.00.02.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,373.79% UpsideDRUGBright Minds Biosciences 3.13Buy$83.25235.55% UpsideFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56590.55% UpsideGNFTGENFIT 3.00Buy$13.00256.16% UpsideCurrent Analyst Ratings BreakdownLatest APLT, DRUG, GNFT, and FDMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/2/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight6/27/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)6/11/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)5/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/14/2025APLTApplied TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.505/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/10/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$460K127.39N/AN/A$0.49 per share0.84DRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AFDMT4D Molecular Therapeutics$40K4,957.31N/AN/A$11.05 per share0.39GNFTGENFIT$76.77M2.38$0.07 per share53.61$1.50 per share2.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-14.56%-14.29%8/13/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)Latest APLT, DRUG, GNFT, and FDMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025APLTApplied Therapeutics-$0.17N/AN/AN/A$0.42 millionN/A8/6/2025Q2 2025FDMT4D Molecular Therapeutics-$0.6922N/AN/AN/A$0.52 millionN/A5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A3.003.00DRUGBright Minds BiosciencesN/A126.01126.01FDMT4D Molecular TherapeuticsN/A12.3612.36GNFTGENFIT0.081.231.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%DRUGBright Minds Biosciences40.52%FDMT4D Molecular Therapeutics99.27%GNFTGENFIT2.24%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%DRUGBright Minds Biosciences42.66%FDMT4D Molecular Therapeutics9.60%GNFTGENFIT4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30141.58 million139.31 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableFDMT4D Molecular Therapeutics12046.33 million41.88 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableAPLT, DRUG, GNFT, and FDMT HeadlinesRecent News About These CompaniesGENFIT (NASDAQ:GNFT) Shares Up 0.7% - Time to Buy?July 10 at 2:20 AM | marketbeat.comGenfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - The Manila TimesJuly 9 at 8:04 PM | manilatimes.netMGenfit: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialJuly 8, 2025 | globenewswire.comGENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) Short Interest Down 25.7% in MayJune 18, 2025 | marketbeat.comGENFIT: June 17, 2025 Combined Shareholders Meeting ResultsJune 17, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports First Quarter 2025 Financial InformationMay 23, 2025 | finanznachrichten.deGENFIT Reports First Quarter 2025 Financial InformationMay 22, 2025 | globenewswire.comGENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in ItalyMay 20, 2025 | globenewswire.comGENFIT S.A.: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 15, 2025 | finanznachrichten.deGENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 14, 2025 | globenewswire.comGenfit: Iqirvo's Success Can't Outweigh ACLF Pipeline RisksMay 12, 2025 | seekingalpha.comGENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory DocumentsMay 7, 2025 | globenewswire.comGENFIT to Present Latest ACLF Research at EASL Congress 2025May 5, 2025 | globenewswire.comGENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-FApril 29, 2025 | globenewswire.comGENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025April 28, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 25, 2025 | finanznachrichten.deGENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 24, 2025 | globenewswire.comGENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holdersMarch 20, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for WeekMarch 14, 2025 | msn.comRoyalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEsMarch 10, 2025 | globenewswire.comGENFIT Announces Revenues and Cash Position as of December 31, 2024February 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonWhy Hims & Hers Is a Buy Below $35 After Its 16% PullbackBy Gabriel Osorio-Mazilli | July 3, 2025View Why Hims & Hers Is a Buy Below $35 After Its 16% PullbackAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIABy Leo Miller | June 12, 2025View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIAAPLT, DRUG, GNFT, and FDMT Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.41 0.00 (-0.05%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.41 0.00 (-0.46%) As of 07/11/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Bright Minds Biosciences NASDAQ:DRUG$24.81 -1.12 (-4.32%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$26.06 +1.25 (+5.02%) As of 07/11/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.4D Molecular Therapeutics NASDAQ:FDMT$4.28 -0.07 (-1.61%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.38 +0.09 (+2.22%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.GENFIT NASDAQ:GNFT$3.65 -0.10 (-2.67%) As of 07/11/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
